Ahmedabad, May 5:
Cadila Healthcare (Zydus Cadila) on Friday informed that the company has received final approval from the US regulator, US Food and Drug Administration (USFDA) to market Budesonide Capsules in 3 mg (Enteric Coated).
The drug is a corticosteroid used for its anti-inflammatory action.
It will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sales for Budesonide is $ 285.8 million (IMS MAT March 2017).
Cadila Healthcare shares gained by over 1 per cent to close at Rs 464 on National Stock Exchange (NSE) on Friday.
(This article was published on May 5, 2017)
Get more of your favourite news delivered to your inbox
Please enter your email. Thank You.
Newsletter has been successfully subscribed.